EMCL is part of the new international initiative „INDICATE“ (INDIvidual CAncer risk depending on HLA TypE) of research groups from Germany, the UK, Finland, and the Netherlands. The aim is to investigate the role of the immune system in tumor development and focus on individuals with the most common inherited cancer syndrome, Lynch syndrome.
The project was initiated at the European Hereditary Tumor Group (EHTG) Meeting 2019 in Barcelona under the lead of Matthias Kloor from the Department of Applied Tumor Biology, Heidelberg. Saskia Haupt from EMCL is responsible for the coordination of the mathematical modeling within this project. By developing mathematical models, EMCL aims at better understanding the underlying mechanisms of the interplay between the immune system and the tumor during tumor development.
INDICATE wants to address as many different human populations and ethnic origins as possible. Such a global initiative is only possible through worldwide collaborations and participation of as many as possible Lynch syndrome centers. Therefore, we are looking forward to expanding our team and involving new collaboration partners from all over the world.
For more information on the project and how to become part of it, please visit the INDICATE website: indicate-lynch.org